QIAGEN leverages QuantiFERON®-TB technology to advance global efforts against TB TB IGRA testing now accessible in high burden, low resource and decentralized settings Study data also showcased at the ...
QIAGEN’s New Generation of QuantiFERON TB Test Gains Chinese Approval and Renewed WHO Recommendation
HILDEN, Germany & GERMANTOWN, Md. & SHANGHAI--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QuantiFERON tuberculosis (TB) testing solution has ...
Venlo, the Netherlands, June 15, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) welcomes the publication of a new, systematic review highlighting the unique value of its ...
Germantown, Md. & HILDEN, Germany & SALUGGIA, Italy--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced the U.S. launch of an automated ...
Jan. 11, 2005 — The U.S. Food and Drug Administration (FDA) has approved a test to identify individual patient variations in drug metabolism; an implant system that simplifies the arthroscopic ...
To describe the use of the second-generation QuantiFERON-TB Gold (QFT-G) test in a series of patients in an ophthalmic practice. The charts of all patients who had QFT-G tests ordered by Mayo Clinic ...
QIAGEN N.V. QGEN recently gained the CE marking of its QuantiFERON SARS-CoV-2 assay, which measures T-cell responses to SARS-CoV-2 and helps evaluate immunity in individuals receiving COVID-19 ...
Disease detection and monitoring technology includes whole-blood lab tests for TB and CMV infections. Qiagen has upped its offer to acquire Australian diagnostics firm Cellestis to A$3.80 per share, a ...
Enabling highly automated screening solution for latent tuberculosis in all throughput segments Embedding QuantiFERON assays in the broad assay menu of DiaSorin’s LIAISON analyzers also gives current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback